查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2070433

細胞和基因治療市場規模、佔有率、成長率、全球產業分析、區域分析和未來預測（2026-2034）

Cell and Gene Therapy Market Size, Share, Growth, Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 220 Pages | 商品交期: 2-3個工作天內

價格

細胞和基因治療市場的成長要素

2025年全球細胞和基因治療市場規模為122.1億美元，預計將從2026年的164.5億美元成長至2034年的1435.5億美元，預測期內複合年成長率高達31.10%。北美市場佔據主導地位，預計到2025年將佔據52.58%的市場佔有率，這主要得益於其強大的生物技術基礎設施、有利的法規結構以及先進治療方法的商業化。

細胞和基因療法是一種突破性的治療方法，它著眼於疾病的根本原因，而非僅僅控制症狀，從而治療癌症、罕見遺傳疾病和慢性疾病。隨著獲批產品數量的持續成長，以及各公司專注於擴大生產擴充性、提高患者可及性、最佳化醫保報銷策略和實現商業化，該市場正步入一個更加成熟的成長階段。

Vertex Pharmaceuticals、諾華、百時美施貴寶、吉利德科學、Krystal Biotech、CRISPR Therapeutics 和羅氏等領先公司正在大力投資研發、策略合作、收購和擴大生產能力，以加強其市場地位。

市場促進因素

罕見遺傳疾病、癌症和慢性病的日益普遍是推動市場成長的主要因素。傳統治療方法往往無法解決這些疾病的根本原因，因此對創新基因編輯和細胞療法的需求十分強勁。

CAR-T療法、基因替代技術、CRISPR治療方法和再生醫學解決方案的成功案例不斷湧現，加速了其在全球的普及應用。此外，對生產基礎設施和臨床研發活動的投入不斷增加，也為市場的長期成長提供了支撐。

市場趨勢

推動該行業發展的主要趨勢之一是向異體移植和預製療法的轉變。與使用患者自身細胞的自體療法不同，異體移植可以預先製備，並根據需要供應。

這種方法有幾個優點：

  • 提高治療的可近性
  • 縮短製造時間
  • 提高擴充性
  • 降低製造成本
  • 簡化配電網路

因此，製藥公司正增加對下一代同種異體移植平台和自動化生產技術的投資。

市場限制因素

儘管成長前景光明，但高昂的治療費用和保險報銷難題仍然是重大障礙。細胞療法和基因療法通常需要高度專業化的生產流程、複雜的物流以及細緻的病患監測，這導致治療費用極為高昂。

許多醫療機構和保險公司仍在評估長期療效，然後才批准廣泛的承保範圍，因此在某些地區，患者的就醫途徑受到限制。

市場機遇

對製造設施和自動化系統投資的增加正在創造巨大的成長機會。大規模擴大生產能力將有助於消除瓶頸、簡化供應鏈，並促進先進治療方法的更廣泛商業化。

多家大型公司正在投資數十億美元建造下一代製造設施，以滿足未來的需求。

市場挑戰

該行業面臨的最大挑戰之一是擴大自體療法的規模。由於每種治療方法都是使用取自患者個體的細胞製造的，因此生產過程仍然複雜、耗時且成本高昂。

確保品質穩定、及時交貨和實現商業規模生產仍然是企業必須克服的關鍵挑戰，才能擴大全球患者的用藥範圍。

基於細分市場的分析

按類型

到 2025 年，細胞療法領域將佔據市場主導地位，這主要得益於 CAR-T 療法的巨大商業性成功以及醫生對細胞療法的信心不斷增強。

一些已獲批准的產品在腫瘤學和血液惡性腫瘤領域佔據了相當大的市場佔有率，從而在該領域取得了主導地位。

隨著基因編輯技術的進步和監管部門的陸續批准，預計基因治療領域在預測期內將以 21.97% 的複合年成長率成長。

最終用戶

到2025年，醫院和診所將佔據最大的市場佔有率。這些機構擁有實施複雜細胞和基因療法所需的專業基礎設施、訓練有素的人員以及病患監測能力。

由於再生醫學和先進治療方法的專業化程度不斷提高，預計到 2034 年，專科診所細分市場將呈現最高的成長率，複合年成長率將達到 32.79%。

區域分析

北美洲

預計到 2025 年，北美市場規模將維持 64.2 億美元，仍將是最大的區域市場。

主要成長要素如下：

  • 一個強大的生物技術生態系統
  • 高昂的醫療費用
  • 正在進行的臨床試驗活動
  • 有利的監管支持

美國市場（2026年）：79.5億美元

歐洲

在歐洲，受慢性病盛行率上升、人口老化以及先進治療方法日益普及的推動，預計到 2026 年，市場規模將達到 44.7 億美元。

  • 德國：10.9億美元（2026年）
  • 英國：7.2億美元（2026年）

亞太地區

在醫療保健基礎設施不斷擴大、研究投資不斷增加以及再生醫學日益普及的推動下，預計到 2026 年，亞太地區的市場規模將達到 21.8 億美元。

  • 中國：7.9億美元（2026年）
  • 日本：4.4億美元（2026年）
  • 印度：1.8億美元（2026年）

近期行業趨勢包括旨在加速商業化和擴大治療機會的策略聯盟、CAR-T 療法的進步、對製造的投資以及企業收購。

目錄

第1章：引言

第2章執行摘要

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章 主要考慮因素

  • 開發用於新適應症的細胞和基因療法
  • 監管情境：按主要國家分類
  • 市場中的技術進步
  • 新產品發布：按主要公司分類
  • 管道分析：按主要公司分類
  • 產業重大發展動態（合併、收購、合作、新產品和服務的推出等）
  • 市場條件下的定價與贖回趨勢
  • 對製造和供應鏈的洞察
  • 投資和資金籌措市場趨勢
  • 摘要：患者獲得治療的機會與倫理考量

第5章：全球細胞與基因治療市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：按類型
    • 細胞療法
      • 治療類型
      • 產品
      • 適應症
    • 基因治療
      • 產品類型
      • 向量的類型
      • 適應症
  • 市場分析、洞察與預測：按最終用戶分類
    • 醫院和診所
    • 專科診所
    • 其他
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美細胞與基因治療市場分析：洞察與預測（2021-2034 年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲細胞與基因治療市場分析：洞察與預測（2021-2034）

  • 國家
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區細胞與基因治療市場分析：洞察與預測（2021-2034）

  • 國家
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家

第9章：拉丁美洲細胞與基因治療市場分析：洞察與預測（2021-2034）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：中東和非洲細胞與基因治療市場分析：洞察與預測（2021-2034 年）

  • 國家
    • 波灣合作理事會（GCC）國家
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Vertex Pharmaceuticals Incorporated
    • Krystal Biotech, Inc.
    • Rocket Pharmaceuticals
    • CRISPR Therapeutics
    • Bayer AG
    • Novartis AG
    • Gilead Sciences, Inc.
    • F. Hoffmann-La Roche Ltd（Spark Therapeutics）
    • Bristol-Myers Squibb Company
    • Adaptimmune
Product Code: FBI114130

Growth Factors of Cell and Gene Therapy Market

The global Cell and Gene Therapy Market was valued at USD 12.21 billion in 2025 and is projected to grow from USD 16.45 billion in 2026 to USD 143.55 billion by 2034, registering a remarkable CAGR of 31.10% during the forecast period. North America dominated the market with a 52.58% market share in 2025, supported by strong biotechnology infrastructure, favorable regulatory frameworks, and increasing commercialization of advanced therapies.

Cell and gene therapies represent a transformative approach to treating cancer, rare genetic disorders, and chronic diseases by targeting the underlying causes of disease rather than merely managing symptoms. The market is entering a more mature growth phase as approved products continue to increase and companies focus on manufacturing scalability, patient access, reimbursement strategies, and commercialization.

Major companies such as Vertex Pharmaceuticals, Novartis, Bristol Myers Squibb, Gilead Sciences, Krystal Biotech, CRISPR Therapeutics, and Roche are investing heavily in research, strategic partnerships, acquisitions, and manufacturing expansion to strengthen their market presence.

Market Drivers

The growing prevalence of rare genetic diseases, cancer, and chronic conditions is a major factor driving market growth. Traditional treatment options often fail to address the root causes of these diseases, creating strong demand for innovative gene-editing and cell-based therapies.

Increasing success of CAR-T therapies, gene replacement technologies, CRISPR-based treatments, and regenerative medicine solutions is accelerating adoption globally. Furthermore, rising investments in manufacturing infrastructure and clinical development activities are supporting long-term market expansion.

Market Trends

A major trend shaping the industry is the transition toward allogeneic and off-the-shelf therapies. Unlike autologous therapies that use a patient's own cells, allogeneic therapies can be manufactured in advance and supplied on demand.

This approach offers several advantages:

  • Improved treatment availability
  • Reduced manufacturing timelines
  • Better scalability
  • Lower production costs
  • Simplified distribution networks

As a result, pharmaceutical companies are increasingly investing in next-generation allogeneic platforms and automated manufacturing technologies.

Market Restraints

Despite strong growth prospects, high treatment costs and reimbursement challenges remain significant barriers. Cell and gene therapies often require highly specialized manufacturing processes, complex logistics, and extensive patient monitoring, leading to exceptionally high treatment costs.

Many healthcare providers and insurance companies continue to evaluate long-term efficacy before approving broad reimbursement coverage, limiting patient access in some regions.

Market Opportunities

Growing investments in manufacturing facilities and automation systems are creating substantial growth opportunities. Expansion of large-scale production capacity will help reduce bottlenecks, improve supply chain efficiency, and support broader commercialization of advanced therapies.

Several leading pharmaceutical companies are investing billions of dollars in next-generation manufacturing facilities to support future demand.

Market Challenges

One of the biggest challenges facing the industry is scaling autologous therapies. Since each therapy is produced using cells collected from individual patients, manufacturing remains complex, time-sensitive, and expensive.

Ensuring consistent quality, timely delivery, and commercial-scale production remains a critical challenge that companies must overcome to expand patient access globally.

Segmentation Analysis

By Type

The Cell Therapy segment dominated the market in 2025 due to the strong commercial success of CAR-T therapies and growing physician confidence in cell-based treatments.

Several approved products have already established a significant market presence in oncology and hematologic cancers, driving segment leadership.

The Gene Therapy segment is expected to grow at a CAGR of 21.97% during the forecast period as gene-editing technologies continue to advance and gain regulatory approvals.

By End User

The Hospitals & Clinics segment accounted for the largest market share in 2025. These facilities possess the specialized infrastructure, trained personnel, and patient monitoring capabilities required for administering complex cell and gene therapies.

The Specialty Clinics segment is projected to grow at the fastest CAGR of 32.79% through 2034 due to increasing specialization in regenerative medicine and advanced therapeutic delivery.

Regional Insights

North America

North America remained the largest regional market with a value of USD 6.42 billion in 2025.

Key growth factors include:

  • Strong biotechnology ecosystem
  • High healthcare spending
  • Robust clinical trial activity
  • Favorable regulatory support

U.S. Market (2026): USD 7.95 billion

Europe

Europe is projected to reach USD 4.47 billion in 2026, supported by rising chronic disease prevalence, an aging population, and increasing adoption of advanced therapies.

  • Germany: USD 1.09 billion (2026)
  • U.K.: USD 0.72 billion (2026)

Asia Pacific

Asia Pacific is expected to reach USD 2.18 billion in 2026, driven by expanding healthcare infrastructure, increasing research investments, and growing adoption of regenerative medicine.

  • China: USD 0.79 billion (2026)
  • Japan: USD 0.44 billion (2026)
  • India: USD 0.18 billion (2026)

Competitive Landscape

The market is highly consolidated, with leading players focusing on product development, strategic collaborations, acquisitions, and manufacturing expansion.

Key companies include:

  • Vertex Pharmaceuticals
  • Novartis
  • Bristol Myers Squibb
  • Gilead Sciences
  • Roche
  • Bayer
  • CRISPR Therapeutics
  • Adaptimmune

Recent industry developments include strategic collaborations, CAR-T therapy advancements, manufacturing investments, and acquisitions aimed at accelerating commercialization and expanding treatment accessibility.

Conclusion

The Cell and Gene Therapy Market is entering a period of unprecedented expansion, driven by rapid technological innovation, increasing regulatory approvals, and growing demand for curative treatments. The market is forecast to grow from USD 12.21 billion in 2025 to USD 143.55 billion by 2034, making it one of the fastest-growing segments within the global biopharmaceutical industry. As manufacturing capabilities improve, reimbursement frameworks evolve, and allogeneic therapies gain traction, the market is expected to unlock significant opportunities across oncology, rare diseases, regenerative medicine, and personalized healthcare.

Segmentation By Type, End User, and Region

By Type * Cell Therapy

    • By Therapy Type
  • CAR-T Cell Therapy
  • TCR-T Cell Therapy
  • Natural Killer (NK) Cells
  • Others
    • By Product
  • Kymriah
  • Yescarta
  • Tecartus
  • Breyanzi
  • Abecma
  • Carvykti
  • Others
    • By Indication
  • Oncology
  • Others
  • Gene Therapy
    • By Vector Type
  • Viral Vectors
  • Non-Viral Vectors
    • By Product Type
  • Zolgensma
  • Luxturna
  • Roctavian
  • Others
    • By Indication
  • Genetic Diseases
  • Ophthalmology
  • Hematology
  • Others

By End User * Hospitals & Clinics

  • Specialty Clinics
  • Others

By Region * North America (By Type, End User, and Country)

    • U.S.
    • Canada
  • Europe (By Type, End User, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Type, End User, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Type, End User, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, End User, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Development of Cell and Gene Therapy for New Disease Indications
  • 4.2. Regulatory Scenarios, By Key Countries/Regions
  • 4.3. Technological Advancements in the Market
  • 4.4. New Product Launches, By Key Players
  • 4.5. Pipeline Analysis, By Key Companies
  • 4.6. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, and Others)
  • 4.7. Pricing & Reimbursement Landscape in the Market
  • 4.8. Manufacturing & Supply Chain Insights
  • 4.9. Investment & Funding Trends in the Market
  • 4.10. Overview: Patient Access to the Therapy & Ethical Considerations

5. Global Cell and Gene Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Cell Therapy
      • 5.1.1.1. Therapy Type
        • 5.1.1.1.1. CAR-T Cell Therapy
        • 5.1.1.1.2. TCR-T Cell Therapy
        • 5.1.1.1.3. Natural Killer (NK) Cells
        • 5.1.1.1.4. Others
      • 5.1.1.2. Product
        • 5.1.1.2.1. Kymriah
        • 5.1.1.2.2. Yescarta
        • 5.1.1.2.3. Tecartus
        • 5.1.1.2.4. Breyanzi
        • 5.1.1.2.5. Abecma
        • 5.1.1.2.6. Carvykti
        • 5.1.1.2.7. Others
      • 5.1.1.3. Indication
        • 5.1.1.3.1. Oncology
        • 5.1.1.3.2. Others
    • 5.1.2. Gene Therapy
      • 5.1.2.1. Product Type
        • 5.1.2.1.1. Zolgensma
        • 5.1.2.1.2. Luxturna
        • 5.1.2.1.3. Roctavian
        • 5.1.2.1.4. Others
      • 5.1.2.2. Vector Type
        • 5.1.2.2.1. Viral Vectors
        • 5.1.2.2.2. Non-Viral Vectors
      • 5.1.2.3. Indication
        • 5.1.2.3.1. Genetic Diseases
        • 5.1.2.3.2. Ophthalmology
        • 5.1.2.3.3. Hematology
        • 5.1.2.3.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By End User
    • 5.2.1. Hospitals & Clinics
    • 5.2.2. Specialty Clinics
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - Region
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. Asia Pacific
    • 5.3.4. Latin America
    • 5.3.5. Middle East & Africa

6. North America Cell and Gene Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Cell Therapy
      • 6.1.1.1. Therapy Type
        • 6.1.1.1.1. CAR-T Cell Therapy
        • 6.1.1.1.2. TCR-T Cell Therapy
        • 6.1.1.1.3. Natural Killer (NK) Cells
        • 6.1.1.1.4. Others
      • 6.1.1.2. Product
        • 6.1.1.2.1. Kymriah
        • 6.1.1.2.2. Yescarta
        • 6.1.1.2.3. Tecartus
        • 6.1.1.2.4. Breyanzi
        • 6.1.1.2.5. Abecma
        • 6.1.1.2.6. Carvykti
        • 6.1.1.2.7. Others
      • 6.1.1.3. Indication
        • 6.1.1.3.1. Oncology
        • 6.1.1.3.2. Others
    • 6.1.2. Gene Therapy
      • 6.1.2.1. Product Type
        • 6.1.2.1.1. Zolgensma
        • 6.1.2.1.2. Luxturna
        • 6.1.2.1.3. Roctavian
        • 6.1.2.1.4. Others
      • 6.1.2.2. Vector Type
        • 6.1.2.2.1. Viral Vectors
        • 6.1.2.2.2. Non-Viral Vectors
      • 6.1.2.3. Indication
        • 6.1.2.3.1. Genetic Diseases
        • 6.1.2.3.2. Ophthalmology
        • 6.1.2.3.3. Hematology
        • 6.1.2.3.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By End User
    • 6.2.1. Hospitals & Clinics
    • 6.2.2. Specialty Clinics
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Country
    • 6.3.1. U.S.
    • 6.3.2. Canada

7. Europe Cell and Gene Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Cell Therapy
      • 7.1.1.1. Therapy Type
        • 7.1.1.1.1. CAR-T Cell Therapy
        • 7.1.1.1.2. TCR-T Cell Therapy
        • 7.1.1.1.3. Natural Killer (NK) Cells
        • 7.1.1.1.4. Others
      • 7.1.1.2. Product
        • 7.1.1.2.1. Kymriah
        • 7.1.1.2.2. Yescarta
        • 7.1.1.2.3. Tecartus
        • 7.1.1.2.4. Breyanzi
        • 7.1.1.2.5. Abecma
        • 7.1.1.2.6. Carvykti
        • 7.1.1.2.7. Others
      • 7.1.1.3. Indication
        • 7.1.1.3.1. Oncology
        • 7.1.1.3.2. Others
    • 7.1.2. Gene Therapy
      • 7.1.2.1. Product Type
        • 7.1.2.1.1. Zolgensma
        • 7.1.2.1.2. Luxturna
        • 7.1.2.1.3. Roctavian
        • 7.1.2.1.4. Others
      • 7.1.2.2. Vector Type
        • 7.1.2.2.1. Viral Vectors
        • 7.1.2.2.2. Non-Viral Vectors
      • 7.1.2.3. Indication
        • 7.1.2.3.1. Genetic Diseases
        • 7.1.2.3.2. Ophthalmology
        • 7.1.2.3.3. Hematology
        • 7.1.2.3.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By End User
    • 7.2.1. Hospitals & Clinics
    • 7.2.2. Specialty Clinics
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.3.1. Germany
    • 7.3.2. U.K.
    • 7.3.3. France
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Scandinavia
    • 7.3.7. Rest of Europe

8. Asia Pacific Cell and Gene Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Cell Therapy
      • 8.1.1.1. Therapy Type
        • 8.1.1.1.1. CAR-T Cell Therapy
        • 8.1.1.1.2. TCR-T Cell Therapy
        • 8.1.1.1.3. Natural Killer (NK) Cells
        • 8.1.1.1.4. Others
      • 8.1.1.2. Product
        • 8.1.1.2.1. Kymriah
        • 8.1.1.2.2. Yescarta
        • 8.1.1.2.3. Tecartus
        • 8.1.1.2.4. Breyanzi
        • 8.1.1.2.5. Abecma
        • 8.1.1.2.6. Carvykti
        • 8.1.1.2.7. Others
      • 8.1.1.3. Indication
        • 8.1.1.3.1. Oncology
        • 8.1.1.3.2. Others
    • 8.1.2. Gene Therapy
      • 8.1.2.1. Product Type
        • 8.1.2.1.1. Zolgensma
        • 8.1.2.1.2. Luxturna
        • 8.1.2.1.3. Roctavian
        • 8.1.2.1.4. Others
      • 8.1.2.2. Vector Type
        • 8.1.2.2.1. Viral Vectors
        • 8.1.2.2.2. Non-Viral Vectors
      • 8.1.2.3. Indication
        • 8.1.2.3.1. Genetic Diseases
        • 8.1.2.3.2. Ophthalmology
        • 8.1.2.3.3. Hematology
        • 8.1.2.3.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By End User
    • 8.2.1. Hospitals & Clinics
    • 8.2.2. Specialty Clinics
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. India
    • 8.3.4. Australia
    • 8.3.5. Southeast Asia
    • 8.3.6. Rest of Asia Pacific

9. Latin America Cell and Gene Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Cell Therapy
      • 9.1.1.1. Therapy Type
        • 9.1.1.1.1. CAR-T Cell Therapy
        • 9.1.1.1.2. TCR-T Cell Therapy
        • 9.1.1.1.3. Natural Killer (NK) Cells
        • 9.1.1.1.4. Others
      • 9.1.1.2. Product
        • 9.1.1.2.1. Kymriah
        • 9.1.1.2.2. Yescarta
        • 9.1.1.2.3. Tecartus
        • 9.1.1.2.4. Breyanzi
        • 9.1.1.2.5. Abecma
        • 9.1.1.2.6. Carvykti
        • 9.1.1.2.7. Others
      • 9.1.1.3. Indication
        • 9.1.1.3.1. Oncology
        • 9.1.1.3.2. Others
    • 9.1.2. Gene Therapy
      • 9.1.2.1. Product Type
        • 9.1.2.1.1. Zolgensma
        • 9.1.2.1.2. Luxturna
        • 9.1.2.1.3. Roctavian
        • 9.1.2.1.4. Others
      • 9.1.2.2. Vector Type
        • 9.1.2.2.1. Viral Vectors
        • 9.1.2.2.2. Non-Viral Vectors
      • 9.1.2.3. Indication
        • 9.1.2.3.1. Genetic Diseases
        • 9.1.2.3.2. Ophthalmology
        • 9.1.2.3.3. Hematology
        • 9.1.2.3.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By End User
    • 9.2.1. Hospitals & Clinics
    • 9.2.2. Specialty Clinics
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.3.1. Brazil
    • 9.3.2. Mexico
    • 9.3.3. Rest of Latin America

10. Middle East & Africa Cell and Gene Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Cell Therapy
      • 10.1.1.1. Therapy Type
        • 10.1.1.1.1. CAR-T Cell Therapy
        • 10.1.1.1.2. TCR-T Cell Therapy
        • 10.1.1.1.3. Natural Killer (NK) Cells
        • 10.1.1.1.4. Others
      • 10.1.1.2. Product
        • 10.1.1.2.1. Kymriah
        • 10.1.1.2.2. Yescarta
        • 10.1.1.2.3. Tecartus
        • 10.1.1.2.4. Breyanzi
        • 10.1.1.2.5. Abecma
        • 10.1.1.2.6. Carvykti
        • 10.1.1.2.7. Others
      • 10.1.1.3. Indication
        • 10.1.1.3.1. Oncology
        • 10.1.1.3.2. Others
    • 10.1.2. Gene Therapy
      • 10.1.2.1. Product Type
        • 10.1.2.1.1. Zolgensma
        • 10.1.2.1.2. Luxturna
        • 10.1.2.1.3. Roctavian
        • 10.1.2.1.4. Others
      • 10.1.2.2. Vector Type
        • 10.1.2.2.1. Viral Vectors
        • 10.1.2.2.2. Non-Viral Vectors
      • 10.1.2.3. Indication
        • 10.1.2.3.1. Genetic Diseases
        • 10.1.2.3.2. Ophthalmology
        • 10.1.2.3.3. Hematology
        • 10.1.2.3.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By End User
    • 10.2.1. Hospitals & Clinics
    • 10.2.2. Specialty Clinics
    • 10.2.3. Others
  • 10.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.3.1. GCC
    • 10.3.2. South Africa
    • 10.3.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Vertex Pharmaceuticals Incorporated
    • 11.2.2. Krystal Biotech, Inc.
    • 11.2.3. Rocket Pharmaceuticals
    • 11.2.4. CRISPR Therapeutics
    • 11.2.5. Bayer AG
    • 11.2.6. Novartis AG
    • 11.2.7. Gilead Sciences, Inc.
    • 11.2.8. F. Hoffmann-La Roche Ltd (Spark Therapeutics)
    • 11.2.9. Bristol-Myers Squibb Company
    • 11.2.10. Adaptimmune

List of Tables

  • Figure 1: Global Cell and Gene Therapy Market Revenue Breakdown (USD Billion, %) by Region, 2025 & 2034
  • Figure 2: Global Cell and Gene Therapy Market Value Share (%), By Type, 2025 & 2034
  • Figure 3: Global Cell and Gene Therapy Market Value Share (%), by End User, 2025 & 2034
  • Figure 4: Global Cell and Gene Therapy Market Value (USD Billion), by Region, 2025 & 2034
  • Figure 5: North America Cell and Gene Therapy Market Value (USD Billion), By Type, 2025 & 2034
  • Figure 6: North America Cell and Gene Therapy Market Value Share (%), By Type, 2025
  • Figure 7: North America Cell and Gene Therapy Market Value (USD Billion), by End User, 2025 & 2034
  • Figure 8: North America Cell and Gene Therapy Market Value Share (%), by End User, 2025
  • Figure 9: North America Cell and Gene Therapy Market Value (USD Billion), By Country, 2025 & 2034
  • Figure 10: North America Cell and Gene Therapy Market Value Share (%), By Country, 2025
  • Figure 11: Europe Cell and Gene Therapy Market Value (USD Billion), By Type, 2025 & 2034
  • Figure 12: Europe Cell and Gene Therapy Market Value Share (%), By Type, 2025
  • Figure 13: Europe Cell and Gene Therapy Market Value (USD Billion), by End User, 2025 & 2034
  • Figure 14: Europe Cell and Gene Therapy Market Value Share (%), by End User, 2025
  • Figure 15: Europe Cell and Gene Therapy Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 16: Europe Cell and Gene Therapy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 17: Asia Pacific Cell and Gene Therapy Market Value (USD Billion), By Type, 2025 & 2034
  • Figure 18: Asia Pacific Cell and Gene Therapy Market Value Share (%), By Type, 2025
  • Figure 19: Asia Pacific Cell and Gene Therapy Market Value (USD Billion), by End User, 2025 & 2034
  • Figure 20: Asia Pacific Cell and Gene Therapy Market Value Share (%), by End User, 2025
  • Figure 21: Asia Pacific Cell and Gene Therapy Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 22: Asia Pacific Cell and Gene Therapy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 23: Latin America Cell and Gene Therapy Market Value (USD Billion), By Type, 2025 & 2034
  • Figure 24: Latin America Cell and Gene Therapy Market Value Share (%), By Type, 2025
  • Figure 25: Latin America Cell and Gene Therapy Market Value (USD Billion), by End User, 2025 & 2034
  • Figure 26: Latin America Cell and Gene Therapy Market Value Share (%), by End User, 2025
  • Figure 27: Latin America Cell and Gene Therapy Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 28: Latin America Cell and Gene Therapy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 29: Middle East & Africa Cell and Gene Therapy Market Value (USD Billion), By Type, 2025 & 2034
  • Figure 30: Middle East & Africa Cell and Gene Therapy Market Value Share (%), By Type, 2025
  • Figure 31: Middle East & Africa Cell and Gene Therapy Market Value (USD Billion), by End User, 2025 & 2034
  • Figure 32: Middle East & Africa Cell and Gene Therapy Market Value Share (%), by End User, 2025
  • Figure 33: Middle East & Africa Cell and Gene Therapy Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 34: Middle East & Africa Cell and Gene Therapy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 35: Global Cell and Gene Therapy Market Share (%), By Company, 2025